Osaka, Japan

Norio Nonomura

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Suita, JP (2020 - 2024)
  • Osaka, JP (2021 - 2024)

Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Norio Nonomura: Innovator in Pharmaceutical Advancements

Introduction

Norio Nonomura is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of kidney diseases and cancer. With a total of 5 patents to his name, Nonomura's work reflects a commitment to advancing medical science.

Latest Patents

Nonomura's latest patents include a drug and production method for treating kidney diseases. This innovative drug contains silicon fine particles, which have hydrogen-generating abilities that can aid in the prevention and treatment of kidney ailments. Another notable patent focuses on a method of treating cancer using an anti-CCR8 antibody that targets tumor-infiltrating cells. This pharmaceutical composition represents a promising approach to cancer treatment.

Career Highlights

Throughout his career, Nonomura has been associated with esteemed institutions such as Osaka University and Shionogi & Company Limited. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Nonomura has worked alongside notable colleagues, including Tetsuya Yoshida and Yujiro Kidani. Their combined expertise has fostered an environment of innovation and discovery in pharmaceutical research.

Conclusion

Norio Nonomura's contributions to the field of pharmaceuticals are noteworthy, particularly in the areas of kidney disease and cancer treatment. His innovative patents and collaborations highlight his dedication to improving medical outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…